Repository logo
 

Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance

Published version
Peer-reviewed

Change log

Authors

Bowden, Anne Ramsay  ORCID logo  https://orcid.org/0000-0003-1138-4452
Morales-Juarez, David A  ORCID logo  https://orcid.org/0000-0001-5370-5512
Sczaniecka-Clift, Matylda 
Agudo, Maria Martin  ORCID logo  https://orcid.org/0000-0003-3605-9963
Lukashchuk, Natalia 

Abstract

CRISPR-Cas9 genome engineering has revolutionised high-throughput functional genomic screens. However, recent work has raised concerns regarding the performance of CRISPR-Cas9 screens using TP53 wild-type human cells due to a p53-mediated DNA damage response (DDR) limiting the efficiency of generating viable edited cells. To directly assess the impact of cellular p53 status on CRISPR-Cas9 screen performance, we carried out parallel CRISPR-Cas9 screens in wild-type and TP53 knockout human retinal pigment epithelial cells using a focused dual guide RNA library targeting 852 DDR-associated genes. Our work demonstrates that although functional p53 status negatively affects identification of significantly depleted genes, optimal screen design can nevertheless enable robust screen performance. Through analysis of our own and published screen data, we highlight key factors for successful screens in both wild-type and p53-deficient cells.

Description

Keywords

Short Report, Genetics and Genomics, CRISPR screening, TP53, DNA damage response, Human

Journal Title

eLife

Conference Name

Journal ISSN

2050-084X

Volume Title

9

Publisher

eLife Sciences Publications, Ltd
Sponsorship
Cancer Research UK (C6/A18796)
Wellcome (206388/Z/17/Z)
Cancer Research UK (C6946/A24843)
Wellcome (WT203144)
Cancer Research UK (C6/A11224)
Consejo Nacional de Ciencia y Tecnología (304302648)
Wellcome (205253/Z/16/Z)